Research article | Open | Published:
Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling
Arthritis Research & Therapyvolume 19, Article number: 183 (2017)
Overexpression of membranous CD154 in T lymphocytes has been found previously in systemic lupus erythematosus (SLE). Because hydroxychloroquine (HCQ) has been used frequently in the treatment of lupus, we sought to identify the effects of HCQ on CD154 and a possibly regulatory mechanism.
CD4+ T cells were isolated from the blood of lupus patients. After stimulation with ionomycin or IL-15 and various concentrations of HCQ, expression of membranous CD154 and NFAT and STAT5 signaling were assessed.
HCQ treatment had significant dose-dependent suppressive effects on membranous CD154 expression in ionomycin-activated T cells from lupus patients. Furthermore, HCQ inhibited intracellular sustained calcium storage release, and attenuated the nuclear translocation of NFATc2 and the expression of NFATc1. However, CD154 expressed through IL-15-mediated STAT5 signaling was not inhibited by HCQ treatment.
HCQ inhibited NFAT signaling in activated T cells and blocked the expression of membranous CD154, but not STAT5 signaling. These findings provide a mechanistic insight into SLE in HCQ treatment.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that has a complex immunological pathogenesis, mainly associated with autoantibody synthesis. Antibody isotype switch and affinity maturation is induced through T-cell-dependent B-cell activation , involving interactions between cell surface CD154 on CD4+ T-helper (Th) cells and CD40 on B cells [2, 3]. Blockade of the CD154/CD40 interaction inhibited T-cell-dependent B-cell proliferation, differentiation, and antibody formation in in-vitro studies and in lupus mouse models [4,5,6]. Thus, rigorous regulation of Th cell CD154 expression is necessary to maintain the antigen specificity and antibody synthesis of the immune response [7,8,9,10].
Overexpression of cell surface CD154 on CD4+ T cells was found in patients with SLE [5, 11,12,13,14,15]. The surface CD154 levels before and after stimulation both increased in active lupus patients when compared with healthy controls or remission lupus patients . The active CD154 expression was associated with SLE disease severity, lupus nephritis, and antibody synthesis [14,15,16]. Furthermore, CD154 gene promoter activity is activation dependent, regulated by the calcineurin-dependent transcription factors of nuclear factor of activated T cells (NFAT), including NFATc2 (NFAT-1) in the early phase and NFATc1 (NFAT-2) in the late phase [3, 7, 10, 14]. Thus, the production of membranous CD154 is mainly mediated through Ca2+-NFAT signaling pathways [17, 18]. In SLE, increased CD154 expression was associated with enhanced intracellular Ca2+ signaling response, NFAT overexpression, NFAT nuclear translocation, and NFAT-mediated CD154 gene transcription [10, 14, 19, 20].
In addition, prolonged CD154 expression is also associated with the interleukin-15 (IL-15) signaling pathway . After IL-15 binding with its receptor, this process activates Jak1 and Jak3 and subsequently phoshorylates STAT5. The phosphorylated STAT5 translocates to the nucleus, engages the CD154 gene promoter, and induces CD154 expression. Overproduction of IL-15 by T cells was observed in SLE patients [22, 23]. IL-15 signaling is therefore another pathway which contributes to CD154 overexpression in SLE. Increased Th cell surface expression of CD154 is reflected in an enhanced capacity to mediate B-cell activation, antigen expression, and autoantibody production [24, 25]. The involvement of the CD40–CD154 interaction pathway in the pathogenesis of SLE has been reported in several studies using human and mouse models [26,27,28].
Hydroxychloroquine (HCQ) was first used for its anti-malaria activity, but has subsequently been used as an anti-rheumatic drug, and is frequently prescribed for SLE patients . HCQ can attenuate SLE disease severity, inflammatory parameters, and immunoglobulin levels in treated patients [30,31,32]. HCQ mainly accumulates in acidic vesicular lysosomes. In antigen-presenting cells, HCQ interfered with the function of the proteosome by increasing the pH of intracellular vacuoles, and also altered the bioactivity of many intracellular proteins [29, 33]. Thus, HCQ blocked antigen presentation and immune synapse between T cells and antigen-presenting cells, and thereafter blocked downstream immune responses . Moreover, in T cells, HCQ has been shown to attenuate T-cell proliferative responses to mitogens, while reducing the release of proinflammatory cytokines through inhibiting Toll-like receptor pathways [33, 35]. Furthermore, HCQ also blocked the T-cell activation pathway by interfering with intracellular calcium signaling . Thus, the diverse immune modulatory effects of HCQ make it widely used in treatment of autoimmune diseases.
CD154 overexpression is associated with enhanced NFAT and STAT5 signaling. It is critical for autoantibody production in SLE patients. Because the overinteraction of CD40–CD154 is detrimental in autoimmune diseases, it had been of great interest in developing targeting therapy [27, 37]. HCQ is the most common medication used in SLE. However, to date there was no previous report about the effect of HCQ on CD154 expression. In this study, we investigated whether HCQ modulated the important membrane protein of CD154 expression in SLE T lymphocytes and its possible underlying mechanisms of action.
Eight healthy control individuals and 27 patients with systemic lupus erythematosus (SLE) who fulfilled at least four of the revised criteria of the American College of Rheumatology were enrolled in this study . The clinical characteristics of the study cohorts are presented in Table 1. SLE disease activity was evaluated by the SLE Disease Activity Index (SLEDAI). The patients with SLEDAI score > 9 were defined as having high disease activity . A total of 20 ml of blood was sampled from each patient for various experiments.
Human peripheral blood mononuclear cells were isolated from sampled heparinized fresh venous blood of SLE donors or healthy controls using Ficoll-paque density gradient centrifugation. In short, 20 ml of fresh blood was collected and spun at 2000 rpm for 10 min at room temperature. Blood plasma (upper fraction) was discarded, while blood cells in the lower fraction were resuspended in an equal volume of phosphate-buffered saline, followed by overlay onto a half volume of Ficoll-paque Plus (17-1440-03; GE Healthcare, Amersham, UK). Cells were centrifuged at 2000 rpm for 20 min at room temperature, resulting in the generation of the peripheral blood mononuclear cell fraction between serum and Ficoll-paque fractions for collection. Subsequently, purified CD4+ T cells were negatively isolated from peripheral blood mononuclear cells by CD4+ T-cell isolation kits (19052; STEMCELL Technologies, Vancouver, Canada) according to the manufacturer’s protocol. In brief, peripheral blood mononuclear cells were washed twice, counted, and resuspended in 2–5 mM cold EDTA isolation buffer at a cell density of 1 × 107 cells/200 μl. Cells were mixed with 10 μl of biotin-Ab cocktail (Abs for cells other than CD4+ T cells) and incubated for 10 min at 4 °C, followed by the addition 20 μl of anti-biotin microbeads. The cell–Ab–microbead reaction mixture was then incubated for 10 min at 4 °C, centrifuged, and cells resuspended in 2 ml of 2.5 mM cold EDTA buffer. For CD4+ T-cell purification, the cell mixture was added through a LS (MACS) column to exclude the cells other than CD4+ T cells.
Medium, buffer, and reagents
Purified T cells were cultured in RPMI-1640-based medium (Gibco/BRL, Carlsbad, CA, USA) supplemented with 1% l-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 10% fetal bovine serum (Hyclone, Logan, UT, USA), 10 mM HEPES, and 50 μM β-mercaptoethanol. Jurkat T cells (clone E6-1) were maintained in complete RPMI medium (10% fetal bovine serum, 100 U/ml penicillin, 100 U/ml streptomycin, and 2 mM glutamine). The isolation buffer was phosphate-buffered saline supplemented with 2 mM EDTA and 2% FBS. The hypotonic RBC lysis buffer consisting of 0.15 M NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA was used to adjust the pH to 7.2, followed by sterilization through 0.22-μm filters and storage at room temperature. Hydroxychloroquine was purchased from Sanofi Pharmaceuticals (Paris, France) and dissolved in sterile water at a concentration of 600 ng/ml (the standard concentration) and stored at −80 °C [30, 40]. In the ionomycin study, ionomycin (I3909; Sigma, St. Louis, MO, USA) was used at 1 or 5 μg/ml while phorbol 12-myrisate 13-acetate (PMA) (P8139; Sigma) was used at 50 ng/ml for T-cell stimulation. In the IL-15 study, cells were stimulated with 1.5 μg/ml polyhydroxyalkanoates (PHA) (L1668; Sigma), 75 ng/ml IL-15 alone (247-ILB; R&D Systems, Minneapolis, MN, USA), or a combination.
In-vitro HCQ treatment of CD4+ T cells and Jurkat cells
The purified CD4+ T cells were isolated by negative selection because positive selection may induce T-cell activation before the experiment. The isolated CD4+ T cells were diluted to a concentration of 1 × 106/ml. We use only SLE samples because the poststimulated CD154 overexpression is critical and more obvious in SLE patients than in healthy controls [14, 17]. Jurkat cells were also diluted to a concentration of 1 × 106/ml for further experiments. The experimental cells, 2 × 105 cells/200 μl, were grown in 96-well tissue culture plates, and then incubated for 24 hours in the presence of various concentrations of HCQ (1 × = 600 ng/ml). Ionomycin is known to cause sustained Ca2+ storage release from the endoplasmic reticulum and to activate intracellular Ca2+ signaling, which is important for CD154 transcription . In the ionomycin study, cells were activated by different concentrations and durations of ionomycin, depending upon the specific experiment. In the IL-15 study, IL-15, PHA, or a combination were used to stimulate T cells. We used stimulation duration of 6 or 20 hours in HCQ inhibition experiments because significant increase of CD154 expression was seen at this stimulation duration in previous studies and our results [14, 21, 42]. After stimulation, cells were stained for CD4, CD154, or NFATc1, according to the manufacturer’s guidelines, and analyzed by flow cytometry.
Flow cytometric analysis
Flow cytometric analysis was performed using a FACS Calibur flow cytometer and CellQuest software (BD Biosciences). The cells were washed and subsequently incubated with the indicated anti-cell surface antibody diluted in 200 μl of blocking buffer at 4 °C for 30 min, spun, and then washed twice with cold phosphate-buffered saline. When staining for intracellular markers, cells were washed, fixed, and permeabilized with commercial fixed/permabilization buffer (00-5123; eBioscience) at 4 °C for 30 min, and then incubated with the indicated antibody at 4 °C for 30 min, spun, and washed twice with cold PBS. Cell staining for flow analysis was performed with the following specific antibodies: anti-human CD4–FITC (catalog no. 555346) and anti-human CD154-PE (catalog no. 555700), purchased from BD Pharmingen. Anti-human NFATc1-PE (lot no. D0612) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell viability assay
Cell viability after culturing in the presence of HCQ was assessed by MTT assay, following the manufacturer’s instructions (Sigma Chemical Co.). In brief, cells were grown for 6 hours in 96-well tissue culture plates (2 × 105 cells/200 μl) and incubated with HCQ in various concentrations. MTT (dimethylthiazolyl-2-5-diphenyltetrazolium bromide) dye solution (Omega, St. Louis, MO, USA) was added 24 hours later and incubated at 37 °C for 2 hours; MTT was reduced by live cells into a colored product. Absorbance at 492 nm wavelength was recorded using Thermo Scientific Multiskan™ GO (Thermo Scientific, Waltham, MA, USA). Each treatment was repeated in quadruplicate. Cell viabilities were defined relative to control cells which were not treated with HCQ, with results used as evaluation of the cytotoxicity of HCQ. The half-maximal cytotoxic concentration (CC50) for each compound was calculated from the dose–response curves with the aid of GraphPad Prism software 5.01 (GraphPad Software, San Diego, CA, USA).
Analysis of intracellular free calcium concentration
Cultured Jurkat T cells, 1 × 105 cells /100 μl, were incubated with different concentrations of HCQ (1 × = 600 ng/ml) or PBS for 24 hours. Fluo-4 Direct™ Calcium Assay Kits (catalog no. F10472; Invitrogen, Carlsbad, CA, USA) were used for measuring the intracellular free calcium concentration. In brief, cells were harvested, precultured with the indicated buffer for 1 hour, and then loaded with the calcium-sensitive indicator dye Fluo-4 Direct™ reagent at 37 °C for 30–60 min following the manufacturer’s protocol. Cells were kept at 4 °C and protected from light prior to analysis. Fluorophore-loaded cells were then stimulated with 1 μg/ml ionomycin and immediately monitored at different time points after stimulation. Intracellular calcium measurements were fluorescently monitored at 494 nm excitation and 516 nm emission by means of a bulk spectrofluorometer (Multiskan™ GO; Thermo Scientific, Waltham, MA, USA).
Nuclear and cytoplasmic protein extraction and western blot analysis
Cell extracts were harvested for western blot analysis after treatments depending upon the specific experiments. In the ionomycin study, the Jurkat cells, 1 × 105 cells/100 μl, were stimulated with 1 μg/ml ionomycin for 2 hours after being pretreated with HCQ for 24 hours. In the IL-15 study, after pretreatment with HCQ for 24 hours, the Jurkat cells were then stimulated with 20 ng/ml IL-15 for 20 min. The cells after stimulation were treated initially on ice with a 200 μl lysis buffer (10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA supplemented with freshly added 1 mM DTT, 0.5 mM PMSF, 2 mM aprotinin, 1 mM leupeptin, 10 mM NaF, and 2 mM Na3VO4) for 15 min. In the IL-15 study, cell extracts were harvested after centrifugation. In the ionomycin study, at the end of the incubation, Nonidet P-40 was added to the reaction mixture at a concentration of 0.6%. The reaction mixture was vortexed for 10 sec and then subjected to centrifugation at 13,000 rpm for 15 sec. The supernatant was saved as cytoplasmic extract. The pellet was resuspended in 25 μl of buffer (20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 2 mM aprotinin, and 1 mM leupeptin) and then shaken for 15 min at 4 °C. After centrifugation for 5 min at 13,000 rpm, the supernatant was stored as nuclear extract (CelLytic NuCLEAR Extraction Kit; Sigma). We followed the manufacturer’s instructions (ECL; Amersham) for the western blot analysis. Anti-human NFATc2 (2172755; Millipore Biotechnology) and anti-human phosphorylated STAT5 (9351; Cell Signaling) were used. The film was scanned, and the density of each band was calculated with QuantityOne software (Bio-Rad).
Purified T cells were treated without or with HCQ of indicated concentration for 24 hours and then stimulated with ionomycin (1 μg/ml) for 20 min. Cells (1 × 106) were transferred onto the glass and fixed by incubation with ice-cold 100% methanol for 10–15 min at room temperature. After washing with PBS (0.25% Triton X-100), cells were blocked with PBST (PBS with 0.1% Tween 20 and 3% BSA) for 30 min at 37 °C. Cells were incubated with anti-human NFATc2 antibody (2172755; Millipore Biotechnology) for 12 hours at 4 °C and then stained with rhodamine-conjugated anti-mouse IgG Ab. Stained cells were examined using a FV1000 confocal microscope (Olympus), and images were processed using Olympus FLUOVIEW software.
The measured items and domain scores for the study groups were presented as mean ± standard deviation. All statistical tests were performed using SPSS-19 software (IBM, Amonk, NY, USA). The flow cytometric data of in-vitro cell culture systems did not fit a Gaussian distribution. Therefore, nonparametric Kruskal–Wallis tests were used to analyze these data to determine whether there were significant differences in the medians of the groups analyzed. If 95% significance was achieved, a paired t test was then used to compare the assay results of one group with another. In all cases, p < 0.05 (two sided) was considered statistically significant. Data from in-vitro cell culture systems were expressed as mean ± SEM of at least three independent experiments, performed in triplicate.
Poststimulated membrane CD154 was overexpressed in SLE patients and associated with SLE disease severity
Previous studies have shown that post-stimulated CD154 expression is clinically associated with ESR and lupus nephritis, but not medications or levels of autoantibodies in SLE patients [14, 15]. The CD154 overexpression in SLE was associated with disease severity . We investigated the clinical association with poststimulated CD154 expression level. The CD154 expression on purified CD4+ T cells from healthy control and SLE patients was analyzed by flow cytometry after ionomycin stimulation for 6 hours. The poststimulated CD154 expression level (percentage and MFI) was significantly higher in SLE patients when compared with healthy controls (Fig. 1). Besides, the percentage of the CD154-expressing cells was significantly higher in lupus patients with high disease activity (SLEDAI score > 9) than in those with lower disease activity (Fig. 1) . Therefore we used purified T cells from SLE patients for the next experiments. Furthermore, the percentage of CD154-expressing cells was higher in patients with lupus nephritis than in those without nephritis, but not significantly (Fig. 1). In addition, the CD154 level did not correlate with age, clinical manifestations, medications, ESR, or autoantibodies.
HCQ treatment has dose-dependent suppressive effects on poststimulated membranous CD154 expression
The previous report revealed that membranous CD154 and soluble CD154 expression in T cells was regulated by different intracellular signal pathways . The membranous CD154 expression mainly depended on the intracellular Ca2+ signaling pathway, which can be stimulated by ionomycin [10, 41]. Because PMA or anti-CD3/CD28 stimulation caused membranous CD154 shedding from cells and attenuated the membranous CD154 expression, we therefore used ionomycin stimulation alone to focus on the Ca2+ signaling pathway. Purified CD4+ T cells were used for the next experiments to avoid secondary effects of cells other than T cells. The purity was 92–97% (Fig. 2a). To verify the role of ionomycin on membranous CD154 expression, purified CD4+ T cells from SLE patients were treated with various concentrations of ionomycin. Our results showed that higher concentrations of ionomycin induced higher levels of membranous CD154 expression (Fig. 2b, left panel). Second, we treated the purified T cells with differing durations of ionomycin exposure, showing that longer ionomycin treatment further upregulated membranous CD154 (Fig. 2b, right panel). The results revealed that the concentration and duration of stimulation conditions was important in CD154 expression. Downregulation of CD154 was noted if the stimulation duration was longer than 24 hours. After 48 hours of stimulation, CD154 expression regained levels similar to those without stimulation. In addition, we performed the same experiments with purified T cells from healthy controls (Fig. 2b). Despite stimulation with various durations or concentrations of ionomycin, T cells from lupus patients expressed higher CD154 than healthy control cells.
To date, no previous study has reported a direct correlation between the membranous CD154 expression and the clinical use of HCQ. In order to assess whether HCQ had a dose-dependent inhibitory effect on CD154 expression in SLE patients, various doses of HCQ were used to treat purified CD4+ T cells from lupus patients in vitro for 24 hours, and then stimulated by 1 μg/ml ionomycin for 6 hours. The expression of CD154 on CD4+ T cells was attenuated gradually when the HCQ concentration was increased. The results showed that higher doses of HCQ had significantly higher inhibition effects on poststimulated membranous CD154 expression, especially when the concentration of HCQ was higher than 5× standard concentration (=3000 ng/ml) (Fig. 2c). Summarily, our results indicate that HCQ has a primary dose-dependent suppressive effect on membranous CD154 expression on CD4+ T cells from SLE patients.
HCQ inhibitory capacity is specific and has limited cytotoxic effects
In the data already presented, we confirmed that HCQ treatment significantly decreased membranous CD154 expression. To investigate the specificity of HCQ effect on CD154 expression, we also evaluate the effect of HCQ on CD4, another membranous molecule of T cells. CD4 was constitutively expressed on the surface of CD4+ T cells. We used various concentrations of HCQ to treated purified CD4+ T cells for 24 hours and measured the CD4 expression level after stimulation with 1 μg/ml ionomycin for 6 hours. We found that HCQ did not inhibit the CD4 expression (percentage and MFI) (Fig. 3a). The inhibitory capacity of HCQ was specific to CD154.
The effective concentrations of HCQ on CD154 expression were defined by the calculation of the half-maximal effective concentration (EC50) from the previous results (Fig. 3b). The EC50 values were determined by plotting the logarithm of HCQ concentration versus relative inhibitory activity. Results showed that HCQ inhibited CD154 expression in CD4+ T cells with 20% reduction at 5× standard concentration (=3000 ng/ml) and more than 50% reduction at 25× standard concentration treatment (Fig. 3b).
However, there was a concern that the results may be due to nonspecific cellular toxicity of HCQ at high doses. Therefore, to determine the effect of the HCQ on cell viability and toxicity, purified CD4+ T cells or Jurkat cells were cultured with increasing concentrations of HCQ for 24 hours and MTT assays were performed to obtain the half-maximal cytotoxic concentration values (CC50) (Fig. 3c, d). We demonstrated that HCQ slightly inhibited T-cell and Jurkat cell viability with less than 10% reduction at 5× standard concentration (=3000 ng/ml) and less than 30% reduction over vehicle control at 25× standard concentration, indicating low toxicity of HCQ in those cells. Abrogating expression of CD154 by HCQ was therefore not due to nonspecific cellular toxicity of HCQ.
HCQ inhibits CD154 expression through inhibition of sustained Ca2+ storage release from the endoplasmic reticulum
In the data already presented, we confirmed that HCQ treatment significantly decreased membranous CD154 expression after ionomycin stimulation, the inducer of intracellular Ca2+ response. The previous study demonstrated that HCQ inhibited the free Ca2+ exflux in Jurkat cell lines and T cells . Therefore we performed in-vitro studies to validate whether HCQ could inhibit sustained Ca2+ storage release after ionomycin stimulation. In our study, various HCQ concentrations were used to treat Jurkat cells and purified T cells for 24 hours, and Ca2+ storage release was measured at different time points after ionomycin stimulation (1 μg/ml). Those results showed significant inhibition of Ca2+ release when HCQ of 10× standard concentration was used (=6000 ng/ml) (Fig. 4). Higher HCQ concentrations were associated with significantly lower Ca2+ release in a dose-dependent manner, as compared with vehicle-treated cells (Fig. 4). In addition, the inhibition effect of HCQ on calcium response lasts for 2 hours. Therefore, HCQ inhibits sustained Ca2+ storage release from the endoplasmic reticulum and subsequent Ca2+ signaling.
In-vitro HCQ treatment decreases NFATc2 nuclear translocation and NFATc1 expression in CD4+ T cells
NFAT is calcineurin dependent and a secondary messenger downstream of the Ca2+ signaling pathway. Previous studies found that increased and prolonged CD154 expression in SLE patients was associated with enhanced NFATc2-mediated CD154 gene transcription . When compared with control, more nuclear translocation of NFATc2 was found in SLE patients and was associated with higher CD154 expression . In the data already presented, we confirmed that HCQ blocked ionomycin induction of CD154 expression and intracellular Ca2+ response. Therefore we wanted to validate whether HCQ could inhibit nuclear translocation of NFATc2. Because a large amount of cells was needed for western blot analysis of NFAT, the immortalized cell line of human T lymphocyte cells (Jurkat cells) was used . After pretreatment with vehicle or 10× standard concentration of HCQ (=6000 ng/ml) for 24 hours and stimulation with ionomycin for 2 hours, the nuclear and cytoplasmic fractions of Jurkat cells were extracted. Western blot analysis was used for examination of the nuclear and cytoplasmic levels of NFATc2. The results showed that the poststimulated NFATc2 level decreased in the nucleus fraction and increased in the cytoplasmic fraction upon HCQ pretreatment when compared with vehicle (Fig. 5a). We demonstrated that HCQ had an inhibitory effect on poststimulated nuclear translocation of NFATc2 in Jurkat cells. Therefore HCQ could abrogate NFATc2 nuclear translocation. To further confirm the inhibitory effect of HCQ on NFATc2 nuclear translocation, we performed immunocytochemistry analysis in purified lupus CD4+ T cells. In the absence of ionomycin stimulation and HCQ treatment, NFATc2 (red) remained in the cytoplasm (Fig. 5b). However, stimulation with ionomycin and PMA led to an increase of NFATc2 translocation into the nucleus. Then we analyzed nuclear translocation of NFATc2 after pretreatment with HCQ at 10× standard concentration (=6000 ng/ml). Upon stimulation, lesser NFATc2 nucleus translocation was found under HCQ pretreatment when compared with negative control (Fig. 5b). These results indicate that HCQ suppresses CD154 expression by inhibiting nuclear translocation of NFATc2 in lupus CD4+ T cells.
Previous studies revealed that NFATc2 is abundant in the cytoplasm of resting T cells, whereas NFATc1 expression is induced by nucleus translocated NFATc2 during T-cell activation [44, 45]. NFATc1 is more predominant than NFATc2 after T-cell activation in pediatric SLE patients and is also responsive for CD154 expression [3, 11, 14]. In the data already presented, we confirmed that HCQ treatment significantly decreased NFATc2 nuclear translocation. Therefore, we examined whether HCQ could inhibit NFATc1 expression. We first applied the experiments on Jurkat cells. Cells were first treated with HCQ at 10× standard concentration (=6000 ng/ml) for 24 hours and then stimulated with ionomycin for 2 hours. The results showed that HCQ significantly decreased NFATc1 expression when HCQ preceded ionomycin treatment (Fig. 5c). Next, using purified CD4+ T cells from lupus patients, we also found that HCQ pretreatment significantly decreased NFATc1 expression in activated CD4+ T cells (Fig. 5d). Because the percentage of NFATc1-expressing T cells was lower after ionomycin stimulation, we performed the same experiments using a stronger stimulus with ionomycin and PMA. A similar result was found that the elevated expression of NFATc1 after stimulation was inhibited by HCQ (Fig. 5d). Therefore, combined with our previous results, we were convinced that HCQ attenuated CD154 expression in SLE patients partially by inhibiting NFAT signaling.
HCQ treatment did not inhibit CD154 expressed through IL-15-mediated STAT5 signaling pathway
Overexpression of IL-15 was noted in SLE patients [22, 23]. IL-15 stimulation can induce prolonged expression of membranous CD154 in T cells through the STAT5 signaling pathway . We investigated whether the HCQ treatment could abrogate IL-15-mediated CD154 expression. Purified CD4+ T cells were first treated with vehicle or HCQ of various concentrations (1 × = 600 ng/ml) for 24 hours and then stimulated with PHA, recombinant IL-15, or a combination for 6 or 20 hours. CD154 expression of T cells was analyzed by flow cytometry. The results showed that the prolonged CD154 expression was not attenuated by HCQ pretreatment (Fig. 6a). Furthermore, we wanted to examine whether HCQ could inhibit STAT5 signaling. Jurkat cells were treated without or with various concentrations of HCQ for 24 hours and stimulated with recombinant IL-15 (75 ng/ml) for 20 min. Western blot analysis was used for measuring the level of phosphorylated STAT5 in cell extracts. We found that the increased phosphorylated STAT5 after IL-15 stimulation did not change upon HCQ pretreatment (Fig. 6b). Therefore the results revealed that HCQ treatment did not inhibit membranous CD154 expressed through the IL-15-mediated STAT5 signaling pathway.
In this study, we found that HCQ could attenuate membranous CD154 expression in activated CD4+ T cells from SLE patients via inhibition of the NFAT signaling pathway (Fig. 7). In SLE patients, CD154 was overexpressed and correlated with disease severity [7, 11, 14, 17, 26]. In our study, we also found that the poststimulated CD154 expression was higher in patients with higher SLE disease activity (Fig. 1). To date, although various previous clinical studies have shown that HCQ is beneficial in reducing the severity and flare of SLE disease, its mechanisms remain largely unknown [46, 47]. We speculated that the HCQ effect in treating SLE patients might be partially due to diminished CD154 expression and blocking the NFAT pathway.
CD154 expression is dependent on the calcium–NFAT pathway. Previous studies showed that the calcium and NFAT signaling response after activation was higher in lupus patients than in healthy controls [14, 20]. In addition, the IL-15–STAT5 signaling pathway is also associated with CD154 expression . Higher serum IL-15 and higher IL-15 secretion from poststimulated T cells were found in SLE compared with the control [22, 23]. Thus, previous studies have shown that poststimulated CD154 expression in T cells of SLE patients is higher than that of healthy controls [14, 15]. T cells from healthy donors have a low level of CD154 expression after stimulation . In our study, we also found that higher CD154 was expressed in lupus patients than in healthy controls despite stimulation with various durations or concentrations (Figs. 1 and 2b).
Previous studies showed a clinical association between the poststimulated CD154 expression and ESR and lupus nephritis, but not medications or level of autoantibodies in SLE patients [14, 28]. Our study also revealed association with lupus nephritis, but not with ESR, medications, and autoantibodies (Fig. 1). The clinical ESR level fluctuated and was easily affected by clinical conditions (such as fever, dehydration, infection) and medication (such as steroid). Furthermore, we found that the CD154 level was higher in patients with lupus nephritis than without nephritis, although not significantly (Fig. 1). The definition of nephritis is different between our study and the previous study. Mehta et al. used a history of biopsy-proven glomerulonephritis as the definition of nephritis [14, 26].We defined proteinuria when blood sampling (daily urine protein > 500 mg/day) indicated nephritis. Besides, some factors are also related to the differences, including no available data of biopsy,pathological type, severity of nephritis and concurrent drugs. Finally, distinct stimulation duration and agents in our study may cause the different results [14, 28]. We use ionomycin stimulation alone for 6 hours but not ionomycin plus PMA stimulation for 24 hours in the previous study . Downregulation of expressed CD154 was noted 24 hours after ionomycin stimulation (Fig. 2b, left panel). The intensity of CD154 expression was lower in our study.
Stimulation with ionomycin and PMA can induce higher CD154 expression than with ionomycin alone. However, ionomycin and PMA regulate the expression of CD154 in different mechanisms . Ionomycin regulates membranous CD154 expression through the calcium pathway and PMA regulates soluble CD154 by the PKC-dependent pathway. PMA induced shedding of membranous CD154 from the T-cell surface, resulting in soluble CD154. In this study, we wanted to investigate the effect of HCQ on the expression of membranous CD154 and focused on the calcium pathway. Therefore we used ionomycin alone without PMA to stimulate cells. Besides, we also measured soluble CD154 after ionomycin stimulation in our experiments (data not shown) and found that soluble CD154 was not detectable after ionomycin stimulation, compatible with previous studies . In contrast, if stimulated with ionomycin + PMA, soluble CD154 was induced and could be inhibited by HCQ pretreatment (data not shown).
In the previous study, the prolonged expression of CD154 after stimulation was noted in T cells isolated from SLE patients taking HCQ . In our study, HCQ inhibited CD154 expression in purified T cells from SLE patients. The different results were due to different experiment methods. In-vitro experiments of HCQ were performed in our study, and ex-vivo experiments were done in previous studies . We used HCQ pretreatment before T-cell stimulation. HCQ in the culture medium had a sustained effect on T cells. In the previous study, they used ex-vivo T cells from SLE patients taking HCQ. When they stimulated T cells, there was no HCQ in the culture medium.
HCQ has been reported to induce apoptosis of peripheral blood T cells from SLE patients . Obvious cell apoptosis was found when treated with HCQ of 30 μg/ml for 24 hours in the previous study . However, cell viability of more than 90% was noted. In our study with purified CD4+ T cells, CD154 expression was significantly inhibited when pretreated with HCQ of 5× standard concentration for 24 hours (Fig. 3a). The expressed CD154 reduced by 20% when compared with vehicle. However, the bioactivity of cells only reduced by less than 10% when 5× HCQ was used (Fig. 3b). Therefore the toxicity of HCQ was limited when a lower concentration was used. In addition, in the IL-15 study, CD154 expression did not decrease even when HCQ of 20× standard concentration was used for pretreatment (Fig. 6a). Besides, we used gated CD4+ cells to analyze the CD154 expression by flow cytometry. The previous study showed that apoptotic cells lost the CD4 surface marker while viable T cells keep cell surface CD4 expression . Therefore, analysis of gated CD4+ cells in our study decreased the interference of apoptotic cells.
Our data demonstrated that HCQ can attenuate NFATc2 nuclear translocation and NFATc1 expression and can inhibit sustained Ca2+ storage release from the endoplasmic reticulum (Figs. 4 and 5). The Ca2+ signaling pathway was important for T-cell activation. Previous studies also showed that HCQ could block activation of T cells from healthy controls and downregulate the activation marker CD69 in vitro . This HCQ effect was due to inhibition of calcium mobilization in a concentration-dependent manner . However, in SLE patients, CD154 overexpression was not simply due to the global activation states of T cells because the activation markers, CD69 and CD25, were not upregulated in SLE [15, 17]. Therefore, as in the previous report, overexpression of CD154 in SLE was largely due to upregulation at the transcriptional level . NFAT is the most important transcription factor for CD154 synthesis [3, 49]. In a previous study, CD154 levels increased in CD4+ T cells from pediatric lupus patients . The enhanced CD154 expression was due to upregulated transcription rates and increased NFAT activity. We reported that inhibition of CD154 expression by HCQ in T cells from SLE patients may be due to directly attenuating the CD154 transcription by inhibiting NFATc2 translocation and NFATc1 expression, not simply due to blocking T-cell activation (Fig. 5). These results may partially explain its efficacy in many autoimmune diseases.
Increased IL-15 production was noted in serum and activated T cells of SLE patients [22, 23]. The IL-15-mediated STAT5 signaling pathway was found to participate in the prolonged CD154 expression . We demonstrated that the HCQ treatment did not attenuate the CD154 expression and STAT5 signaling after IL-15 stimulation (Fig. 6). This finding was not compatible with a previous report that the STAT5 expression level in T cells was lower in SLE patients receiving HCQ treatment . However, in that previous study, STAT5 levels were associated with SLE disease activity. The lower STAT5 in the HCQ treatment group may be due to decreased disease activity but not directly inhibited by HCQ.
The etiology of SLE is mainly due to production of pathogenic autoantibodies. This process requires T-cell help, along with the interaction of CD154 (on the T-cell surface) with CD40 (on the B-cell surface), which is critical for B-cell survival and proliferation, memory generation, and, most importantly, antibody synthesis [1, 3, 11]. Furthermore, recent data from SLE patients and murine lupus models have demonstrated that increased and prolonged expression of membranous CD154 enhanced its capacity to mediate excessive B-cell activation and autoantibody formation [7, 14, 26]. Therefore, at present, there is extensive research into CD154 as a target for therapy in SLE. Both cyclosporine and dipyridamole could inhibit CD154 expression and were demonstrated effective in SLE treatment . Treatment with anti-CD154 mAbs prior to disease onset in SLE mouse models prolongs survival, prevents development of proteinuria, ameliorates kidney disease, and decreases anti-DNA autoantibody titers [16, 27, 51, 52]. Moreover, in the diagnosed SLE, anti-CD154 treatment slows down disease progression, reverses proteinuria, and induces remissions in mice even when lupus nephritis has already developed. HCQ was used to treat SLE for decades and has proven to have a significant effect in disease control and the maintenance of remission . Our study demonstrates that HCQ could abrogate CD154 expression through inhibiting the NFAT pathway in T cells; to our knowledge, this is a newly reported SLE therapeutic effect of HCQ, which may partially explain why HCQ has been well suited for SLE drug therapy.
HCQ treatment has a dose-dependent suppressive effect on CD154 expression in T cells of SLE patients because of its inhibitory effect on NFAT, rather than the STAT5 signaling pathway. These results indicate why HCQ is a first-line therapy as an anti-rheumatic drug, and further provides mechanistic evidence for HCQ being highly recommended for the treatment of SLE.
Erythrocyte sedimentation rate
Nuclear factor of activated T cells
Systemic lupus erythematosus
SLE Disease Activity Index
Signal transducer and activator of transcription 5
Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol. 1992;149:3817–26.
Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR, et al. Molecular and biological characterization of a murine ligand for CD40. Nature. 1992;357:80–2.
Cron RQ. CD154 transcriptional regulation in primary human CD4 T cells. Immunol Res. 2003;27:185–202.
Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest. 2003;112:1506–20.
Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, Vaishnaw A, Davidson A. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 2002;46:1554–62.
Xu H, Liu J, Cui X, Zuo Y, Zhang Z, Li Y, Tao R, Li Y, Pang J. Increased frequency of circulating follicular helper T cells in lupus patients is associated with autoantibody production in a CD40L-dependent manner. Cell Immunol. 2015;295:46–51.
Crow MK, Kirou KA. Regulation of CD40 ligand expression in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13:361–9.
Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996;153:85–106.
Howard LM, Miller SD. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease. Autoimmunity. 2004;37:411–8.
Kyttaris VC, Zhang Z, Kampagianni O, Tsokos GC. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 2011;63:2058–66.
Alaaeddine N, Hassan GS, Yacoub D, Mourad W. CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin Dev Immunol. 2012;2012:490148.
Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum. 1999;42:871–81.
Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun. 2006;26:165–71.
Mehta J, Genin A, Brunner M, Scalzi LV, Mishra N, Beukelman T, Cron RQ. Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis. Arthritis Rheum. 2010;62:2499–509.
Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996;97:2063–73.
Santos-Argumedo L, Alvarez-Maya I, Romero-Ramirez H, Flores-Romo L. Enforced and prolonged CD40 ligand expression triggers autoantibody production in vivo. Eur J Immunol. 2001;31:3484–92.
Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest. 1996;98:826–37.
Vavassori S, Covey LR. Post-transcriptional regulation in lymphocytes: the case of CD154. RNA Biol. 2009;6:259–65.
Kyttaris VC, Wang Y, Juang YT, Weinstein A, Tsokos GC. Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol. 2007;178:1960–6.
Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol. 1995;155:2269–81.
Lowe RM, Genin A, Orgun N, Cron RQ. IL-15 prolongs CD154 expression on human CD4 T cells via STAT5 binding to the CD154 transcriptional promoter. Genes Immun. 2014;15:137–44.
Baranda L, de la Fuente H, Layseca-Espinosa E, Portales-Perez D, Nino-Moreno P, Valencia-Pacheco G, Abud-Mendoza C, Alcocer-Varela J, Gonzalez-Amaro R. IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:1507–13.
Aringer M, Stummvoll GH, Steiner G, Koller M, Steiner CW, Hofler E, Hiesberger H, Smolen JS, Graninger WB. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford). 2001;40:876–81.
Bijl M, Horst G, Limburg PC, Kallenberg CG. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis. 2001;60:523–6.
Harigai M, Hara M, Fukasawa C, Nakazawa S, Kawaguchi Y, Kamatani N, Kashiwazaki S. Responsiveness of peripheral blood B cells to recombinant CD40 ligand in patients with systemic lupus erythematosus. Lupus. 1999;8:227–33.
Yellin MJ, Thienel U. T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep. 2000;2:24–31.
Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, Davidson A. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum. 2003;48:495–506.
Yellin MJ, D’Agati V, Parkinson G, Han AS, Szema A, Baum D, Estes D, Szabolcs M, Chess L. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum. 1997;40:124–34.
Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5:S4–10.
Sailler L, Puissant B, Meliani P, Castex JO, Saivin S, Adoue D, Fournie B, Arlet P, Montastruc JL, Lapeyre-Mestre M, et al. Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients. Ann N Y Acad Sci. 2007;1108:41–50.
Willis R, Seif AM, McGwin Jr G, Martinez-Martinez LA, Gonzalez EB, Dang N, Papalardo E, Liu J, Vila LM, Reveille JD, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus. 2012;21:830–5.
de Sanctis JB, Garmendia JV, Chaurio R, Zabaleta M, Rivas L. Total and biologically active CD154 in patients with SLE. Autoimmunity. 2009;42:263–5.
Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–33.
Lombard-Platlet S, Bertolino P, Deng H, Gerlier D, Rabourdin-Combe C. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell. Immunology. 1993;80:566–73.
Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol. 1993;20:803–8.
Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000;95:3460–6.
Pinelli DF, Ford ML. Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. Immunotherapy. 2015;7:399–410.
Eng M. Tan, Alan S. Cohen, James F. Fries, Alfonse T. Masi, Dennis J. Mcshane, Naomi F. Rothfield, Jane Green Schaller, Norman Talal, Robert J. Winchester. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism. 1982;25(11):1271–1277
Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32:1107–18.
Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460–9.
Matthies KM, Newman JL, Hodzic A, Wingett DG. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol. 2006;241:47–58.
Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol. 1993;151:2497–510.
So JS, Kim GC, Song M, Lee CG, Park E, Kim HJ, Kim YS, Jun CD, Im SH. 6-Methoxyflavone inhibits NFAT translocation into the nucleus and suppresses T cell activation. J Immunol. 2014;193:2772–83.
Timmerman LA, Healy JI, Ho SN, Chen L, Goodnow CC, Crabtree GR. Redundant expression but selective utilization of nuclear factor of activated T cells family members. J Immunol. 1997;159:2735–40.
Zhou B, Cron RQ, Wu B, Genin A, Wang Z, Liu S, Robson P, Baldwin HS. Regulation of the murine Nfatc1 gene by NFATc2. J Biol Chem. 2002;277:10704–11.
Costedoat-Chalumeau N, Amoura Z, Hulot JS, Lechat P, Piette JC. Hydroxychloroquine in systemic lupus erythematosus. Lancet. 2007;369:1257–8.
The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150–4.
Meng XW, Feller JM, Ziegler JB, Pittman SM, Ireland CM. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum. 1997;40:927–35.
Brandt C, Liman P, Bendfeldt H, Mueller K, Reinke P, Radbruch A, Worm M, Baumgrass R. Whole blood flow cytometric measurement of NFATc1 and IL-2 expression to analyze cyclosporine A-mediated effects in T cells. Cytometry A. 2010;77:607–13.
Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res Ther. 2014;16:R23.
Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997;159:3104–8.
Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol. 1998;160:2158–65.
The authors thank Dr Michael Chan for helpful discussion and critical reading of the manuscript.
No funding was received.
Availability of data and materials
No supporting data.
Ethics approval and consent to participate
This human subjects study protocol was approved by the Institutional Review Board of the Buddhist Tzu Chi General Hospital (BTZH IRB No.: B10302004), and written informed consent (according to the Declaration of Helsinki) was obtained from all participating individuals.
Consent for publication
The consent for publication was obtained from all authors.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.